SecBot SecBot

ANIK

Anika Therapeutics, Inc.
Nasdaq· Surgical & Medical Instruments & Apparatus· Inc. DE· CIK 0000898437 Biotech & Drug Discovery
$12.92 −0.48 (−3.58%)
Nov 16 4:00 PM ET · prev $13.40
Market cap
$179.5M
Micro cap
Consensus
Buy
88% Buy or better · 8 analysts
Median target
$20.00
+55% · range $17.00–23.00
1 year
+33.9%
from $9.65 · Nov 17
30 days
−36.1%
from $20.22
52-week range
$9.13–22.03
−41% from high · low Jan 28
Avg volume 20D
124.3K
Oct 20 spike 363.0K
Short interest
323.5K
≈2.4% of shares · −11.5%
Days to cover
3.1
at average volume
Insider net
+$264.3K
3 buyers · 0 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
13
analyzed by SecBot
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/2

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    3 insiders bought $264.3K at an average $13.76. No open-market sales. Price is 6% below their cost.

  • InstitutionsMIXED

    Q3 2026: 11 added (0 new), 12 trimmed or exited.

  • AnalystsBULLISH

    7 of 8 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest −11.5% to 323.5K shares. 3.1 days to cover, ≈2.4% of shares.

  • TrendDOWNTREND

    34% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
GEODE CAPITAL MANAGEMENT, LLCADD419,172$8.2M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPDOUBLED255,568$5.0M
UBS Group AGTRIM87,107$1.7M
Assenagon Asset Management S.A.TRIM40,376$793.8K
MARSHALL WACE, LLPADD31,197$613.3K
STRS OHIOADD29,700$583.9K
AMERICAN CENTURY COMPANIES INCTRIM29,470$579.4K
LOS ANGELES CAPITAL MANAGEMENT LLCDOUBLED12,900$253.6K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

8 analysts
Buy 88% rate it Buy or better
Strong Buy3Buy4Hold1Sell0Strong Sell0
12-month targets · 2 analysts

Price is below the lowest target. Median implies +55%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 16, 2026🔒 Fresh data, subscribers only
REITERATE
REITERATE
Jul 30, 2026B. Riley Securities
MAINTAIN
MAINTAINBuy

Washington

Corporate Lobbying

2 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$264.3K
bought · 3 insiders
$0
sold · 0 insiders
−6.1%
vs their $13.76 cost
DateInsiderTypeValue
Aug 4, 2026
Fischetti Gary P
Director
Aug 4, 2026
BUY$20.3K
Aug 3, 2026
Fischetti Gary P
Director
Aug 3, 2026
BUY$20.7K
Jun 18, 2026
Capper Joseph H
Director
Jun 18, 2026
AWARD10,402 sh
Jun 18, 2026
HENNEMAN JOHN B III
Director
Jun 18, 2026
AWARD10,402 sh
Jun 18, 2026
CONLEY SHERYL L
Director
Jun 18, 2026
AWARD10,402 sh
Jun 18, 2026
Richard Stephen
Director
Jun 18, 2026
AWARD10,402 sh
Jun 18, 2026
Fischetti Gary P
Director
Jun 18, 2026
AWARD10,402 sh
May 1, 2026
HENNEMAN JOHN B III
Director
May 1, 2026
BUY$73.3K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
323,508
shares short
-11.5%
vs prior settlement
3.1
days to cover
≈2.4%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 6, 2026 SEC
Anika Therapeutics reported Q3 2026 revenue of $30.6M (+10% YoY), slightly above the $29.4M consensus, with Commercial…
8-K · Impact 6/10
Nov 6, 2026 Earnings
Anika Reports Third Quarter 2026 Financial Results
Revenue Increased 10% Year Over Year, Led by 17% Commercial Channel Growth Including More Than 30% G
Oct 22, 2026 SEC
Anika Therapeutics Inc. announced it will report its Q3 2026 results on November 6, 2026.
PRESS-RELEASE · Impact 1/10
Sep 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC · ADD
419,172 shares ($8.2M)
Sep 30, 2026 Inst.
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP · DOUBLED
255,568 shares ($5.0M)
Aug 4, 2026 Insider
Fischetti Gary P bought 1,000 shares
Director @ $20.32 ($20.3K)
Aug 3, 2026 Insider
Fischetti Gary P bought 1,000 shares
Director @ $20.75 ($20.7K)
Jul 29, 2026 SEC
Anika Therapeutics reported a transformative Q2 2026 beat, with GAAP EPS of $0.24 (vs $0.03 consensus) and revenue of…
8-K · Impact 8/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
4 drugs tracked · Drug pipeline →
Recent

SecBot reports

13 filings · 1 bullish · 1 bearish · 4 mixed · 7 neutral
All ANIK filing & press-release reports (13)